The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomized, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. Interest around TB-402, which is given as a single injection post surgery and has several weeks of activity, is due to its potential to overcome the major drawbacks, such as spontaneous bleeding and the need for extensive patient monitoring, associated with current anti-coagulant therapy.
ThromboGenics and its development partner BioInvent plan to engage in discussions with potential partners for TB-402.
During this period, additional data from the earlier successful Phase I studies were presented at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) on July 15, 2009 in Boston by Professor Peter Verhamme from KULeuven.
TB-403 (RG7334) - Novel anti-cancer agent partnered with Roche - Partnership with Roche continues to run smoothly with TB-403 Phase Ib enrolment completed recently
In June 2008, ThromboGenics and its co-development partner BioInvent signed a strategic alliance deal with Roche for its novel anti-cancer agent, TB-403 (anti-PIGF). The partnership continues to run smoothly and enrolment for the Phase Ib trial was completed in the second quarter of 2009. This Phase Ib trial is assessing TB-403's tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer.
The results from this trial are currently planned to be presented at a scientific conference later this year.
In January 2009, ThromboGenics and BioInvent received their first success
fee from Roche based on the successful transfer and implementation of
technology and process development for TB-403 production. ThromboGenics
received EUR3 million (60%) of the overall EUR5 million
|SOURCE ThromboGenics NV|
Copyright©2009 PR Newswire.
All rights reserved